Clinical Trials
A clinical trial is currently evaluating Glyceryl tridecanoate in an ongoing, actively recruiting registry study focused on primary and idiopathic triglyceride deposit cardiomyovasculopathy. Sponsored by academic and medical organizations, including the Translational Research Center for Medical Innovation Kobe Hyogo Japan and the Osaka University Graduate School of Medicine, this observational effort has no assigned phase. The initiative aims to collect clinical data to advance understanding of this rare metabolic cardiovascular condition.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05345223 | Recruiting | Triglyceride Deposit Cardiomyovasculopathy |
Translational Research Center for Medical Innovation Kobe Hyogo Japan|Osaka University Graduate School of Medicine |
2022-03-31 | -- |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Jump to
- Glyceryl tridecanoate Solubility in DMSO
- Glyceryl tridecanoate Stock Solution
- Glyceryl tridecanoate Storage
- Glyceryl tridecanoate Stability
- Glyceryl tridecanoate Molecular Weight
- Glyceryl tridecanoate SMILES
- Glyceryl tridecanoate CAS Number
- Glyceryl tridecanoate Chemical Structure (2D and 3D)
- Glyceryl tridecanoate SDS|MSDS